Title :

Does early disease progression predicts survival after first line-treatment of Waldenström macroglobulinemia?

Author(s) :

Labreuche, Julien [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Service de Biostatistiques [CHRU Lille]
Assouan, Deborah [Auteur]
CHU Amiens-Picardie
Durot, Eric [Auteur]
Hôpital universitaire Robert Debré [Reims] [CHU Reims]
Tomowiak, Cécile [Auteur]
Centre hospitalier universitaire de Poitiers = Poitiers University Hospital [CHU de Poitiers [La Milétrie]]
Roos-Weil, Damien [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Toussaint, Elise [Auteur]
Centre Hospitalier Universitaire [Strasbourg] [CHU Strasbourg]
Bijou, Fontanet [Auteur]
Institut Bergonié [Bordeaux]
Lemal, Richard [Auteur]
Centre d'Investigation Clinique [CHU Clermont-Ferrand] [CIC 1405]
Brion, Annie [Auteur]
Service d'Hématologie [CHRU Besançon]
Laribi, Kamel [Auteur]
Centre Hospitalier Le Mans (CH Le Mans)
Ysebaert, Loic [Auteur]
Service Hématologie - IUCT-Oncopole [CHU Toulouse]
Duhamel, Alain [Auteur]
Service de Biostatistiques [CHRU Lille]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Morel, Pierre [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
CHU Amiens-Picardie
Centre Hospitalier de Lens

Journal title :

Hematological Oncology

Abbreviated title :

Hematol Oncol

Publication date :

2022-04-07

ISSN :

1099-1069

English keyword(s) :

progression
survival
Waldenstrom macroglobulinemia

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

In symptomatic Waldenström macroglobulinemia (sWM) patients, prognosis is assessed with the international prognostic scoring system (IPSSWM). In follicular lymphoma and other B-cell and T-cell lymphomas, disease progression ...
Show more >In symptomatic Waldenström macroglobulinemia (sWM) patients, prognosis is assessed with the international prognostic scoring system (IPSSWM). In follicular lymphoma and other B-cell and T-cell lymphomas, disease progression within 24 months (POD24) or (in patients without POD24) after 24 months has been proposed as the start date for stratifying subsequent survival. In the present report, we assessed in a large series of 472 sWM patients, the prognostic value of this new dynamic endpoint already reported in many other lymphomas subtypes. The 3 year subsequent survival for patients with POD24 was 75% and 93% for patients without POD24. In sWM patients, departure from the proportional hazards assumption complicated this analysis. In patients without POD24, the median subsequent progression-free survival time of 43 months accounted for favorable outcome, whereas survival after progression was not influenced by the time to progression. In addition, sensitivity analysis showed that the baseline IPSSWM score also influenced survival after POD24. In sWM patients, we conclude that the apparent difference in survival after POD24 or the 24 months time-point (in patients without POD24) is mainly explained by the prolonged subsequent progression free survival of latter patients. Indeed, the mortality after progression is not influenced by the time to this event.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
CHU Lille

Collections :

• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Submission date :

2023-11-15T04:21:36Z
2024-01-16T09:31:48Z
2024-01-16T09:32:50Z